Premium
Can mandatory pretransfusion approval programmes be improved?
Author(s) -
Hawkins T. E.,
Carter J. M.,
Hunter P. M.
Publication year - 1994
Publication title -
transfusion medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.471
H-Index - 59
eISSN - 1365-3148
pISSN - 0958-7578
DOI - 10.1111/j.1365-3148.1994.tb00242.x
Subject(s) - cryoprecipitate , blood component , medicine , fresh frozen plasma , audit , blood transfusion , intensive care medicine , transfusion medicine , platelet , surgery , business , accounting
SUMMARY. To improve the appropriateness of blood‐component prescribing, a mandatory haematologist pretransfusion approval programme of all non‐red‐cell components was instituted. This was associated with a 33% decrease in the units of fresh frozen plasma (FFP) transfused. Platelet transfusions increased but utilization of both platelets and FFP are now the lowest of the six comparable blood transfusion regions in New Zealand. A subsequent concurrent audit, using preset criteria, of FFP, cryoprecipitate and platelet usage over a 3‐month period showed that further reductions in blood component usage could still be achieved, despite the continuing pretransfusion approval policy. This audit showed that 33% of FFP and 30% of cryoprecipitate units transfused were inappropriately given, despite prior haematologist approval. Hospital transfusion practices can be improved by mandatory blood‐component pretransfusion approval but concurrent auditing of this programme is required to identify and correct continuing inappropriate blood‐component prescribing. Haematologists need to agree on blood‐component indications prior to instituting a pretransfusion approval programme in order to provide optimal management.